Nektar Therapeutics (NKTR) Posts Q2 EPS Loss of $0.32, Revenues 60% Y/Y
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $71.04 +10.33%
EPS Growth %: +26.6%
Financial Fact:
Other income (expense), net: 332K
Today's EPS Names:
CRMT, More
EPS Growth %: +26.6%
Financial Fact:
Other income (expense), net: 332K
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.32), $0.01 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $17.3 million versus the consensus estimate of $14.89 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
- Trip.com Group (TCOM) Misses Q1 EPS by 41c
- Constellation Brands (STZ) Tops Q1 EPS by 18c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
